Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies involving 52 705 women with breast cancer and 108 411 women without breast cancer

dc.contributor.author	Collaborative Group on Hormonal Factors in Breast Cancer
dc.date.accessioned	2021-12-13T17:30:47Z
dc.date.accessioned	2022-03-18T01:52:23Z
dc.date.available	2021-12-13T17:30:47Z
dc.date.available	2022-03-18T01:52:23Z
dc.date.issued	1997
dc.description.abstract	For almost half a century various oestrogens and progestagens have been prescribed to replace the cyclical production of ovarian hormones that normally ceases at the menopause. In the early years such hormone replacement therapy (HRT) was mostly in the form of oestrogenic compounds, but other hormones, mostly progestagens, have been increasingly used in combination with oestrogens. The relation between risk of breast cancer and use of HRT has been investigated in many epidemiological studies.1“1 The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and reanalysed the worldwide data on this topic.	es_CR
dc.description.pages	1047-1059
dc.description.uri
dc.identifier.issn	0140-6736
dc.identifier.uri	https://repositorio.sibdi.ucr.ac.cr/handle/123456789/17441
dc.language.iso	eng	es_CR
dc.publisher	The Lancet, No.350	es_CR
dc.subject	CANCER	es_CR
dc.subject	ENFERMEDADES	es_CR
dc.subject	EPIDEMIOLOGIA	es_CR
dc.title	Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies involving 52 705 women with breast cancer and 108 411 women without breast cancer	es_CR
dc.type	Article	es_CR

Archivos

Mostrando 1 - 1 de 1

Nombre:: Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies involving 52705. Rosero.pdf
Tamaño:: 781.9 KB
Formato:: Adobe Portable Document Format

Mostrando 1 - 1 de 1